Syndecan-4 identified as novel target for asthma treatment [PreClinical] – 2 Minute Medicine


2 Minute Medicine

Syndecan-4 identified as novel target for asthma treatment [PreClinical]
2 Minute Medicine
Study Rundown: Asthma, an immune system disorder characterized by airway inflammation and difficulty breathing, affects about 25 million people in the United States alone. Both long- and short-term medications are available for regulating inflammation

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.